NLRP3 and Alzheimer disease: While regulation of Nlrp3 inflammasome assembly and activation may be a potential therapeutic approach, it is currently unknown whether targeting inflammasome activation in AD will result in a beneficial or detrimental effect on clinical outcomes such as cognitive measures.